| Revenue | DKK 6,3M | +49% |
| EBITDA | DKK 1,7M | +45% |
| Net profit | DKK 1,3M | +45% |
| Total assets | DKK 3M | +35% |
| Equity | DKK 1,6M | +32% |
| Employees | 7 | — |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 452 | 2.339 | 3.665 | 5.174 | 3.554 | 2.647 | 3.305 | 4.260 | 6.333 |
| Staff expenses | -490 | -1.714 | -3.035 | -4.032 | -3.675 | -2.314 | -2.447 | -3.113 | -4.669 |
| EBITDA | -38 | 625 | 630 | 1.142 | -121 | 333 | 859 | 1.147 | 1.665 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -38 | 625 | 630 | 1.142 | -121 | 333 | 859 | 1.147 | 1.665 |
| Net financials | -1 | -2 | -5 | -9 | -10 | -2 | -5 | -10 | -14 |
| Profit before tax | -38 | 623 | 624 | 1.133 | -131 | 331 | 854 | 1.137 | 1.651 |
| Tax | -8 | 146 | 139 | 251 | -27 | 74 | 188 | 251 | 365 |
| Net profit | -30 | 476 | 485 | 882 | -104 | 258 | 666 | 886 | 1.286 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 732 | 1.352 | 2.064 | 2.900 | 1.247 | 1.327 | 2.810 | 2.187 | 2.953 |
| Equity | 50 | 526 | 612 | 1.094 | 190 | 448 | 913 | 1.199 | 1.586 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 70 | 241 | 0 | 0 |
| Short-term debt | 682 | 825 | 1.453 | 1.806 | 1.058 | 809 | 1.656 | 987 | 1.367 |
| Total debt | 682 | 825 | 1.453 | 1.806 | 1.058 | 880 | 1.897 | 987 | 1.367 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KE Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
NJ Management | Management | 2014 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Epista Life Science A/S | Company | 100.0% | 100.0% | 2022 |
NIELS STENTOFT HOLDING ApS | Company | 50.0% | 50.0% | 2014 |
| Person | Role here | Other companies |
|---|---|---|
| Klavs Esbjerg | Chief Executive Officer | 0 companies |
| Niels Jacob Stentoft | Management | 0 companies |